Trial watch for HCC

这个日志已经过期。这里是 2020 年的更新。

---1st line---

RATIONALE 301 (百济神州/BeiGene) tislelizumab vs sorafenib

HIMALAYA (AstraZeneca) durvalumab or durvalumab+tremelimumab vs sorafenib

LEAP-002 (MSD+Eisai) lenvatinib + pembrolizumab vs lenvatinib

COSMIC-312 (Exelixis) cabozantinib + atezolizumab vs sorafenib vs cabozantinib

SHR-1210-III-310 (恒瑞) SHR-1210+apatinib vs sorafenib

EMERALD-1 (AstraZeneca) TACE+durvalumab±bevacizumab vs TACE + placebo

ORIENT-32 (信达/Innovent) sintilimab (IBI308)+IBI305 vs sorafenib

CheckMate 9DW (BMS) nivolumab + ipilimumab vs sorafenib

CS1003 (基石) CS1003 + lenvatinib vs placebo + lenvatinib

---2nd line---

KEYNOTE-394 (MSD) pembrolizumab vs placebo in Asian pts.

---Adjuvant---

CheckMate 9DX (BMS) nivolumab vs placebo

EMERALD-2 (AstraZeneca) durvalumab+bevacizumab vs durvalumab+placebo vs placebo

KEYNOTE-937 (MSD) pembrolizumab vs placebo

JUPITER 04 (君实/Junshi) Toripalimab vs placebo

IMbrave050 (Roche) atezolizumab + bevacizumab vs none therapy